ACHIEVEMENT OF LOW DISEASE ACTIVITY IN PATIENTS INITIATING INFLIXIMAB WITH AND WITHOUT DOSE ESCALATION

被引：0
|
作者：
Cohen, S. [1 ]
Reed, G. [2 ]
Magner, R. [3 ]
Kafka, S. [4 ]
Ellis, L. [4 ]
DeHoratius, R. J. [5 ]
Greenberg, J. D. [6 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] LLC Mass Med Sch, Corrona, Southborough, MA USA
[3] U Mass Med Sch, Worcester, MA USA
[4] Janssen Sci Affairs LLC, Horsham, PA USA
[5] Horsham Phila, LLC Kimmel Sch Med, Janssen Sci Affairs, Horsham, PA USA
[6] NYU, LLC, Sch Med, Corrona, Southborough, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.2771
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0156
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [11] SIBDQ Score Does Not Predict the Need for Dose Escalation of Infliximab in Inflammatory Bowel Disease Patients
    Parian, Alyssa M.
    Thul, Bonny
    Dudley-Brown, Sharon
    Lazarev, Mark
    GASTROENTEROLOGY, 2012, 142 (05) : S660 - S660
  • [12] Time of infliximab therapy initiation and dose escalation in Crohn's disease
    Lam, Mindy C. W.
    Lee, Terry
    Atkinson, Kenneth
    Bressler, Brian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (01) : 214 - 218
  • [13] Time of infliximab therapy initiation and dose escalation in Crohn's disease
    Mindy CW Lam
    Terry Lee
    Kenneth Atkinson
    Brian Bressler
    World Journal of Gastroenterology, 2014, (01) : 214 - 218
  • [14] Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
    Hisamatsu, Tadakazu
    Kunisaki, Reiko
    Nakamura, Shiro
    Tsujikawa, Tomoyuki
    Hirai, Fumihito
    Nakase, Hiroshi
    Watanabe, Kenji
    Yokoyama, Kaoru
    Nagahori, Masakazu
    Kanai, Takanori
    Naganuma, Makoto
    Michimae, Hirofumi
    Andoh, Akira
    Yamada, Akihiro
    Yokoyama, Tadashi
    Kamata, Noriko
    Tanaka, Shinji
    Suzuki, Yasuo
    Hibi, Toshifumi
    Watanabe, Mamoru
    INTESTINAL RESEARCH, 2018, 16 (03) : 494 - +
  • [15] Infliximab dose escalation in patients with rheumatoid arthritis in the START study: Influence of Infliximab pharmacokinetics and immunogenicity
    Rahman, M. U.
    Strusberg, I.
    Geusens, P.
    Wagner, C.
    Han, J.
    Westhovens, R.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 86 - 86
  • [16] No effect of dose escalation of infliximab in patients with rheumatoid arthritis with residual activity - Data from national registry
    Pavelka, K.
    Tegzova, D.
    Pavelkova, A.
    Vencovsky, J.
    Jarosova, K.
    Forejtova, S.
    Chroust, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 56 - 56
  • [17] Infliximab dose escalation in RA patients: PK & immunogenicity in the start trial
    Westhovens, R.
    Rahman, M. U.
    Strusberg, I.
    Geusens, P.
    Berman, A.
    Wagner, C.
    Fasanmade, A.
    Xu, S.
    Han, J.
    RHEUMATOLOGY, 2008, 47 : II15 - II15
  • [18] Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
    Rahman, Mahboob U.
    Strusberg, Ingrid
    Geusens, Piet
    Berman, Alberto
    Yocum, David
    Baker, Daniel
    Wagner, Carrie
    Han, John
    Westhovens, Rene
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1233 - 1238
  • [19] Comparison of Dose Escalation and Co-therapy Intensification between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab
    Thorne, Carter
    Boire, Gilles
    Chow, Andrew
    Garces, Kirsten
    Poulin-Costello, Melanie
    Walker, Valery
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1171 - 1171
  • [20] WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS THAT REQUIRE EARLY DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Salem, Mark
    Ha, Christina
    Syal, Gaurav
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S27 - S27
12345